Stockscreener 앱 받기
1.99
5.24%
-0.11
시간 외 거래:
1.99
전일 마감가:
$2.10
열려 있는:
$2.01
하루 거래량:
50,185
Relative Volume:
1.31
시가총액:
$18.36M
수익:
-
순이익/손실:
$-20.74M
주가수익비율:
-0.7928
EPS:
-2.51
순현금흐름:
$-18.90M
1주 성능:
-15.32%
1개월 성능:
-7.44%
6개월 성능:
-33.70%
1년 성능:
-34.11%
1일 변동 폭
$1.8706
$2.1925
1주일 범위
$1.8706
$2.36
52주 변동 폭
$1.8706
$4.20
Lisata Therapeutics Inc Stock (LSTA) Company Profile
명칭
Lisata Therapeutics Inc
전화
908-229-2590
주소
110 ALLEN ROAD, BASKING RIDGE
LSTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
1.99 | 18.36M | 0 | -20.74M | -18.90M | -2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Lisata Therapeutics Inc 주식(LSTA)의 최신 뉴스
Neostem stock plunges to 52-week low at $2.01 amid market challenges - Investing.com India
Lisata Therapeutics CEO discusses AI drug discovery collaborationICYMI - Proactive Investors
Lisata Therapeutics expands drug discovery with GATC AI collaboration - Proactive Investors USA
Lisata Therapeutics to Present at the Investival Showcase USA - The Manila Times
Can This Clinical-Stage Pharma Company Transform Solid Tumor Treatment? CEO Presents Next Month - StockTitan
Lisata Therapeutics and GATC Health Consummate First Step - GlobeNewswire
Market movers: General Motors, Moderna, CrowdStrike, Lisata... - Proactive Investors UK
Lisata Therapeutics And GATC Health Partner To Accelerate Drug Development Using AI Technology - Nasdaq
Lisata Therapeutics partners with GATC Health to advance AI-driven drug development - Proactive Investors UK
Can AI Revolutionize Lisata's Pancreatic Cancer Drug? New GATC Health Partnership Aims to Prove It - StockTitan
Neostem stock hits 52-week low at $2.15 amid market challenges - Investing.com Australia
Neostem stock hits 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa
Lisata Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid Financial Challenges - GuruFocus.com
Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid ... - Yahoo Finance Australia
Lisata Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Earnings call transcript: Lisata Therapeutics Q4 2024 sees steady progress By Investing.com - Investing.com South Africa
Lisata Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Lisata Therapeutics Q4 2024 sees steady progress - Investing.com India
Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q4 2024 Earnings Call Transcript - Insider Monkey
Lisata Therapeutics CEO: 2025 to be ‘data-rich’ as certepetide trials progress - Proactive Investors UK
Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Can Lisata's Promising Pancreatic Cancer Treatment Offset Its $20M Annual Losses? - StockTitan
Lisata Therapeutics Inc expected to post a loss of 76 cents a shareEarnings Preview - TradingView
Endometriosis Pipeline Drugs Analysis Report: FDA Approvals, - openPR.com
Lisata Therapeutics (LSTA) Expected to Announce Quarterly Earnings on Thursday - Defense World
LSTALisata Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Lisata Therapeutics to Report Full Year 2024 Financial - GlobeNewswire
Lisata Therapeutics Earnings Call: 2024 Results and Corporate Update on Feb 27 - StockTitan
Lisata Therapeutics to Report 2024 Financial Results and Host Conference Call on February 27, 2025 - Nasdaq
Lisata Therapeutics, Inc. (NASDAQ:LSTA) Sees Significant Decline in Short Interest - Defense World
Lisata reports positive early trial results for pancreatic cancer drug - MSN
Refractory Angina Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Gene Biotherapeutics, XyloCor Therapeutics, Centocor, Lisata Therapeutics - The Globe and Mail
Lisata Therapeutics (NASDAQ:LSTA) Trading Up 0.8% – Here’s What Happened - Defense World
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference - GlobeNewswire
Lisata Therapeutics CEO to present at 2025 BIO CEO & Investor Conference - Proactive Investors USA
Lisata's Cancer Treatment Pipeline Takes Center Stage at Major Biotech Investor Conference - StockTitan
Lisata completes subject enrolment in multi-cancer trial of certepetide - MSN
Lisata falls after mid-stage data for anticancer agent - MSN
Lisata Therapeutics CEO discusses recent pancreatic cancer trial milestones – ICYMI - Proactive Investors UK
Lisata reports positive early trial results for pancreatic cancer drug By Investing.com - Investing.com Australia
Lisata Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Lisata Therapeutics CEO David Mazzo on ASCEND and iLSTA Trial Results - Proactive Investors USA
Lisata Therapeutics CEO David Mazzo on ASCEND and iLSTA trial results - Proactive Investors USA
Lisata Therapeutics and WARPNINE Announce Encouraging - GlobeNewswire
Lisata Therapeutics and WARPNINE unveil positive preliminary results from pancreatic cancer trial - Proactive Investors USA
Lisata Therapeutics Inc (LSTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10.70%
자본화:
|
볼륨(24시간):